Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2010

View Archived Issues

Pharmaxis acquires Topigen and issues 3.2 million shares

Dainippon Sumitomo Pharma offers quarterly update

Insight into the mechanistic and molecular basis of entecavir resistance in HBV

Lung Rx and ImmuneWorks sign development agreement for IW-001 in IPF and PGD

Synergistic antitumor effects of tumor-targeted superantigen combined with anti-CTLA-4

Merck & Co. discloses novel HIV integrase inhibitors

New PAI-1 inhibitors identified by Kowa

Novel neuroprotective agent Indip shows promise in stroke model

Vitae Pharmaceuticals identifies new renin inhibitors

MAP initiates PK study of Levadex in smokers and nonsmokers

TopoTarget discloses novel NMPRTase inhibitors

Tyrosine kinase inhibitors for cancer therapy disclosed by Merck KGaA

Embera and Exponential sign clinical development agreement for EMB-001C

U.K. MHRA approves Oncolytics' phase III trial of Reolysin in head and neck cancers

Quark granted orphan drug designation for QPI-1002 in DGF in kidney transplants

FDA approves REMS for erythropoiesis-stimulating agents

Prezista approved for pediatric use in Canada

Athersys completes enrollment in phase I trial of stem cell therapy MultiStem in AMI

ImmuneRegen and Fred Hutchinson Cancer Research Center to initiate homspera trials

PARI Pharma begins enrollment in phase IIb L-CsA trial in bronchiolitis obliterans

Alkermes reports phase I results of ALKS-37 in opioid-induced constipation

Novel selective and orally active inhibitors of PKB show potent antitumor effects in vivo

ERYtech and M.D. Anderson Cancer Center to develop biomarker assay for personalized treatment

Wyeth discloses the discovery of novel PARP-1 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...